Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RET | P07949 | 1/20 | 0.37 |
| ▸ | CTSS | P25774 | 1/20 | 0.33 |
| ▸ | CTSC | P53634 | 4/20 | 0.32 |
| ▸ | CTSK | P43235 | 1/20 | 0.32 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.30 |
| ▸ | LTB4R | Q15722 | 1/20 | 0.30 |
| ▸ | LTB4R2 | Q9NPC1 | 1/20 | 0.30 |
| ▸ | HRH3 | Q9Y5N1 | 1/20 | 0.30 |
| ▸ | ALOX12 | P18054 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL20205769 | 0.89 | RET (0.33) | RET | |
| SCHEMBL20068845 | 0.85 | RET (0.35) | RET | |
| SCHEMBL20206064 | 0.84 | RET (0.40) | RETCTSCCTSKKCNH2LTB4R | |
| SCHEMBL20069014 | 0.84 | RET (0.36) | RETCTSCKCNH2LTB4RLTB4R2 | |
| SCHEMBL20068840 | 0.73 | SCN1A (0.33) | RET | |
| SCHEMBL20069012 | 0.73 | RET (0.44) | RETCTSSCTSK | |
| SCHEMBL20069071 | 0.71 | SCN1A (0.35) | RET | |
| SCHEMBL20070401 | 0.71 | CYP2D6 (0.34) | RETHRH3 | |
| SCHEMBL17749033 | 0.70 | OPRM1 (0.36) | KCNH2 | |
| SCHEMBL13103020 | 0.70 | DRD2 (0.40) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2023-05-16 | — | — | US | disclosed |
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | ARRAY BIOPHARMA INC. (US) | 2021-01-05 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-10881652-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885CTSS 4551/4885CTSC 3852/4885 |
| US-11648243-B2 | Substituted pyrazolo[1,5-A]pyridine compounds as RET kinase inhibitors | RET, BRAF, RAF1 | RET 1/4885CTSS 4551/4885CTSC 3852/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.